Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 5 institutions in 2 countries.
Meng WangExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-0780-5608
Adeline DehlingerExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-6611-114X
Camila Fernández ZapataExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0003-4795-6053
Maya GolanNeuroimmunology and Multiple Sclerosis Unit and Laboratory, Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Gerardina GallaccioExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-1060-5244
Leif E SanderDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.ORCID 0000-0002-0476-9947
Stephan SchlickeiserInstitute of Medical Immunology, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, and Berlin Institute of Health Berlin, Berlin, Germany.
Desiree KunkelFlow&MassCytometry Core Facility, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-0054-955X
Tanja Schmitz-HübschExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Birgit SawitzkiTranslational Immunology, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
Arnon KarniNeuroimmunology and Multiple Sclerosis Unit and Laboratory, Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.ORCID 0000-0002-5625-7900
Julian BraunSi-M / "Der Simulierte Mensch" a science framework of Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-7788-8154
Lucie LoyalSi-M / "Der Simulierte Mensch" a science framework of Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-5738-4437
Andreas ThielSi-M / "Der Simulierte Mensch" a science framework of Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-5515-4002
Judith Bellmann-StroblExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0003-2615-1643
Friedemann PaulExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Lil Meyer-ArndtNeuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Chotima BöttcherExperimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany. chotima.boettcher@charite.de.ORCID 0000-0002-6226-586X
Max Delbrück Center · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEHumboldt-Universität zu Berlin · DETel Aviv Sourasky Medical Center · ILTel Aviv University · IL
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although these treatments are known to predispose patients to infections and affect their responses to vaccination, little is known about the impact of DMTs on the myeloid cell compartment. In this study, we use mass cytometry to examine DMT-associated changes in the innate immune system in untreated and treated patients with MS (n = 39) or NMOSD (n = 23). We also investigated the association between changes in myeloid cell phenotypes and longitudinal responsiveness to homologous primary, secondary, and tertiary SARS-CoV-2 mRNA vaccinations. Multiple DMT-associated myeloid cell clusters, in particular CD64
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases. · full record | Socratic